Premium
Treatment modality selection and prognosis of early stage small cell lung cancer: retrospective analysis from a single cancer institute
Author(s) -
Zhu H.,
Zhou Z.,
Xue Q.,
Zhang X.,
He J.,
Wang L.
Publication year - 2013
Publication title -
european journal of cancer care
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.849
H-Index - 67
eISSN - 1365-2354
pISSN - 0961-5423
DOI - 10.1111/ecc.12082
Subject(s) - medicine , carboplatin , etoposide , lung cancer , chemotherapy , stage (stratigraphy) , radiation therapy , hazard ratio , surgery , cisplatin , multivariate analysis , retrospective cohort study , oncology , confidence interval , paleontology , biology
We evaluated the role of surgery followed by either chemotherapy ( ChT ) alone or chemotherapy and thoracic radiotherapy ( ChT/TRT ) versus sequential ChT/TRT in patients with clinical stage I or stage II small cell lung cancer ( SCLC ). Ninety‐six patients received surgery (complete resection) followed by either ChT alone or ChT/TRT ( G roup I ), while 49 patients were treated exclusively with sequential ChT/TRT ( G roup II ). The ChT regimens consisted of either carboplatin/etoposide or cisplatin/etoposide. The total TRT dose was 50–60 Gy . For the whole group ( n = 145), the median survival time was 54 months, and the 5‐year overall survival ( OS ) rate was 48%. The corresponding figures for G roup I were 91 months and 57%, respectively, and for G roup II , they were 34.6 months and 31.4% respectively ( P = 0.004). Multivariate analysis revealed that a K arnofsky P erformance S tatus score ≥ 80 [hazard ratio ( HR ), 0.281; P = 0.015] and the treatment modality including surgery ( HR , 0.503; P = 0.004) were independent favourable prognostic factors for OS .